This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here.
Bristol-Myers (BMY) reported results last week, beating on both revenue and earnings per share. The company has a long history of exceeding guidance, and even raised 2020 estimates look beatable this year. In the quarter, the company earned $1.63 (vs $1.49 estimates, and up an eye-popping 38% year over year).
The Celgene deal was obviously enormously accretive as we discussed in our initiation piece a year